Hypertension remains a major burden and presents acute challenges in patient care. Sympathetic renal denervation (RDN) emerged as a therapeutic option for patients with resistant hypertension, until Symplicity HTN-3. However, more recently three sham-controlled trials have shed new light on RDN. In this Independent Medical Education webinar, four leading authorities discuss the scientific basis for RDN, the implications of data from SPYRAL OFF, RADIANCE SOLO and SPYRAL ON, its durability, safety and the considerations in patient selection, and look at what lies ahead.
Professor Andrew Sharp (Moderator) is a Consultant Cardiologist at the Royal Devon and Exeter Hospital, and was appointed Honorary Associate Professor at the University of Exeter, UK in 2018. Professor Sharp is a research programme lead in several areas, including hypertension, renal denervation, ischaemic heart disease, intracoronary imaging, coronary physiology, pulmonary embolus and aortic valve disease. He trained at Edinburgh Medical School, Imperial College Hospitals and San Raffaele Hospital, Milan, and received his MD postgraduate research degree from Imperial College London for work on hypertensive heart. Professor Sharp has served as Principal Investigator in more than 30 research trials since 2012 and has published extensively.
Dr Indranil Dasgupta is a Consultant Nephrologist at Heart of England NHS Foundation Trust, and is an Honorary Senior Lecturer at the University of Birmingham, UK. His research interests include treatment resistant hypertension. Dr Dasgupta is Clinical Research Lead Division 2 for Renal, Stroke, CVD, Diabetes and Metabolic Diseases for the West Midlands in NIHR Clinical Research Network, Honorary Secretary of the Renal Association UK, and a member of the research working party for the British and Irish Hypertension Society. Dr Dasgupta also serves as an expert adviser for the National Institute for Health and Care Excellence.
Professor Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and Cardiology at Saarland University Hospital, and Affiliate/Visiting Professor Harvard-MIT Biomedical Engineering, Institute of Medical Engineering and Science, Cambridge, US. Professor Mahfoud completed training in Cardiology and Interventional Cardiology at the Department for Internal Medicine III, Saarland University Hospital, Germany in 2014. Since 2017, he has served as Vice Chairman of the ‘Working Group on Interventional Hypertension Treatment’ for the European Society of Hypertension, and as a Committee Member of the 2018 Hypertension Guidelines.
Professor Atul Pathak is Head of Hypertension, Clinique Pasteur, Toulouse, France. He also leads a clinical research team focusing on cardiovascular pathophysiology and clinical pharmacology and is affiliated with the National Institute of Medical Research. A pharmacologist and cardiologist, Professor Pathak currently serves as Vice President of the European Society for Patient Care (SETE). He was a resident in cardiology from 1996 to 2001 and trained in Toulouse (France), Aachen (Germany) and at the Cleveland Clinic, US.
This webinar will inform and educate on:
- Hypertension – the burden and current unsolved challenges in patient care
- Sympathetic modulation and the scientific basis for renal denervation
- Early data on the use of catheter-based renal denervation
- Symplicity HTN-3. Where and why did it all go wrong?
- The comeback! What do the three sham-controlled trials recently published tell us about the state of play in RDN?
- So RDN works. What do we need to know now?
- Outcomes and future need
- Interventional cardiologist
- Hypertension specialists
- Interventional Fellows
- Registrars with an interest in interventional cardiology
Funding to produce this webinar was provided by an unrestricted grant from: